Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of Sunitinib in Sarcomas of the Central Nervous System

NCT03641326 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03641326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03641326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of Sunitinib in Sarcomas of the Central Nervous System
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
February 21, 2019
Completion date
April 2, 2021
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system sarcoma, gliosarcoma